ClinicalTrials.gg
CompletedNCT00224510Updated May 30, 2017

A Study To Investigate The Antidepressant Effect Of Lamotrigine In Patients With Bipolar Disorder Using Lithium

A Phase 3 interventional study of lamotrigine in Bipolar Disorder and Bipolar Depression, sponsored by GlaxoSmithKline. Completed at 31 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-30.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 1 month after the study started (first participant enrolled Aug 2002, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing lamotrigine in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Lamotrigine · Bipolar Disorder.

Enrollment
10th of 33
120 · median 72
Started
2002
with 3 others
Phase 3
11 of 33
none open now
Registered
12th of 33
by date
Lead sponsor
9 of 33
GlaxoSmithKline

Among the 33 studies testing lamotrigine in Bipolar Disorder, this one is the 10th largest by enrollment, is one of 4 that started in 2002, is one of 11 in phase 3, and was the 12th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

None of the 33 studies testing lamotrigine in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →

About lamotrigine

Lamotrigine: first FDA approval 1994 (LAMICTAL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies testing lamotrigine in Bipolar Disorder as a file.
02

Study summary

This is a study that, in the first 16 weeks, investigates whether lamotrigine versus placebo offers effect on depressive episodes for patients with bipolar disorder (also known as manic depressive disorder) who use lithium. In the following 50 weeks it is investigated whether these patients experience effect on their depressive and/ or (hypo)manic episodes.

Read the detailed description

A Multicentre, Double-Blind, Randomised, Fixed-Dose Evaluation of the Safety and Efficacy of Lamotrigine (Lamictal®) compared to placebo as add-on therapy to lithium in the Treatment of Bipolar Depression followed by Long-term Prevention of Relapse and Recurrence of Depression and/or Mania in Subjects With Bipolar Disorder

03

Conditions studied

  • Bipolar Disorder
  • Bipolar Depression

Browse trials for

Keywords

  • bipolar disorder bipolar depression lamotrigine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with bipolar disorder (type I or type II) currently suffering from depression that is at least moderate in severity according to a psychiatrist.
  • Currently using lithium.
  • Female subjects can't be pregnant or become pregnant during the study.

Exclusion criteria

Exclusion criteria:

  • Actively suicidal.
  • Rapid cyclers.
  • Suffering from significant personality disorders.
  • Alcohol or substance dependent or abusive.
  • Suffering from significant physical conditions.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
120 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Score on the MADRS depression rating scale at week 8 compared to baseline

Secondary outcomes

  1. Scores on various mood rating scales and safety measurements at week 16 and between week 16 and week 68 compared to baseline

07

Study locations

31 sites
  • GSK Investigational Site
    Alkmaar, 1815 JD, Netherlands
  • GSK Investigational Site
    Almelo, 7609 PP, Netherlands
  • GSK Investigational Site
    Amersfoort, 3818 EW, Netherlands
  • GSK Investigational Site
    Amsterdam, 1061 AE, Netherlands
  • GSK Investigational Site
    Amsterdam, 1075 GB, Netherlands
  • GSK Investigational Site
    Bennebroek, 2121 AD, Netherlands
  • GSK Investigational Site
    Blaricum, 1261 AN, Netherlands
  • GSK Investigational Site
    Delft, 2625 AD, Netherlands
  • GSK Investigational Site
    Den Haag, 2553 RJ, Netherlands
  • GSK Investigational Site
    Dordrecht, 3317 NM, Netherlands
  • GSK Investigational Site
    Eindhoven, 5623 EJ, Netherlands
  • GSK Investigational Site
    Enschede, 7511JX, Netherlands
  • GSK Investigational Site
    Gouda, 2803 RT, Netherlands
  • GSK Investigational Site
    Groningen, 9713 GZ, Netherlands
  • GSK Investigational Site
    Hoorn, 1624 NP, Netherlands
  • GSK Investigational Site
    Leiden, 2333 ZB, Netherlands
  • GSK Investigational Site
    Nijmegen, 6532 SZ, Netherlands
  • GSK Investigational Site
    Raalte, 8102 RR, Netherlands
  • GSK Investigational Site
    Retranchement, 4525 LG, Netherlands
  • GSK Investigational Site
    Rosmalen, 5248 NT, Netherlands
  • GSK Investigational Site
    Tilburg, 5022 GC, Netherlands
  • GSK Investigational Site
    Utrecht, 3512 PG, Netherlands
  • GSK Investigational Site
    Vlissingen, 4382 EE, Netherlands
  • GSK Investigational Site
    Weert, 6001 BE, Netherlands
  • GSK Investigational Site
    Zwolle, 8025 AB, Netherlands
  • GSK Investigational Site
    Alava, 01004, Spain
  • GSK Investigational Site
    Barcelona, 08025, Spain
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Madrid, 28035, Spain
  • GSK Investigational Site
    Valencia, 46009, Spain
08

References and documents

Publications

  • Poster presented at the APA congress, US, 2007 (Lamotrigine as add-on to lithium in bipolar depression) and the 5th European Stanley Conference on Bipolar Disorder in Barcelona, 2006)
  • van der Loos ML, Mulder PG, Hartong EG, Blom MB, Vergouwen AC, de Keyzer HJ, Notten PJ, Luteijn ML, Timmermans MA, Vieta E, Nolen WA; LamLit Study Group. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009 Feb;70(2):223-31. doi: 10.4088/jcp.08m04152. Epub 2008 Dec 30. PubMed 19200421 ↗
  • van der Loos ML, Mulder P, Hartong EG, Blom MB, Vergouwen AC, van Noorden MS, Timmermans MA, Vieta E, Nolen WA; LamLit Study Group. Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. Acta Psychiatr Scand. 2010 Sep;122(3):246-54. doi: 10.1111/j.1600-0447.2009.01537.x. Epub 2010 Feb 5. PubMed 20136801 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2002 to primary completion in Sep 2006, 49 months.

Of 29 industry-sponsored phase 3 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 49. This study's 49 months is above that.

Counting every sponsor, half of 43 studies reached it within 37 months; a quarter within 21 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2005
First posted
Sep 23, 2005
StartActual
Aug 2002
Primary completionActual
Sep 2006
CompletionActual
Sep 2006
Last update
May 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00224510
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 23, 2005
Start date
Aug 2002
Primary completion
Sep 2006
Completion
Sep 2006
Last update
May 30, 2017

Study contacts

GSK Clinical Trials, MD
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamotrigine

Start the discussion